Home
Search
Search Results
Previously Searched
3102 results found
Expand All
Apply All
3102 results found

BIO Presents Sen. John Thune (R-S.D.) Legislator of the Year Award
Press Release  •  February 28, 2017
The Biotechnology Innovation Organization (BIO) today presented Senator John Thune (R-S.D.) its Industrial & Environmental Section Legislator of the Year Award, recognizing the Senator’s steadfast commitment to growing South Dakota’s and the nation’s biobased economy.
Read More

BIO Submits Comments to EMA on Strategies to Identify and Mitigate Risks for First-In-Human and Early Clinical Trials with Investigational Medicinal Products
Letters, Testimony & Comments  •  February 28, 2017
The Biotechnology Innovation Organization (BIO) thanks the European Medicines Agency (EMA) for the opportunity to submit comments on the “Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.” 
Read More

BIO's Testimony in Opposition to Maryland's House Bill 666
Letters, Testimony & Comments  •  February 27, 2017
Patrick Plues, BIO’s Vice President, State Government Affairs, testified before the Maryland House in opposition to House Bill 666, which would require biopharmaceutical manufacturers to disclose specific information on cost inputs for specific drugs and to provide 60-day prior notice of any anticipated price increase for products priced over a certain threshold.
Read More

BIO Submits Amicus Brief in Wi-Fi One, LLC v. Broadcom Corporation (U.S. Court of Appeals for the Federal Circuit)
Amicus Brief  •  February 23, 2017
BIO Submits Brief of Amicus Curiae in Wi-Fi One, LLC v. Broadcom Corporation (U.S. Court of Appeals for the Federal Circuit)
Read More

BIO and Croplife International Submit Amicus Brief in Impression Products Inc. v. Lexmark International Inc. (U.S. Supreme Court)
Amicus Brief  •  February 23, 2017
BIO and Croplife International Submit Brief of Amicus Curiae in Impression Products Inc. v. Lexmark International Inc. (Supreme Court of the United States)
Read More

BIO Submits Comments on EPA’s Proposed Denial of Petitions for Rulemaking to Change the RFS Point of Obligation
Press Release  •  February 22, 2017
In BIO’s view, granting the petitions to change the point of obligation would create unnecessary regulatory uncertainty and fail to further the statutory goals of the Renewable Fuel Standard (“RFS”) program.
Read More

Nominations Now Open for the BIO George Washington Carver Award for Innovation in Industrial Biotechnology
Press Release  •  February 22, 2017
The ninth annual George Washington Carver Award will recognize an individual who has made a significant contribution to building the biobased economy by applying industrial biotechnology to create sustainable and environmentally sustainable products. The Biotechnology Innovation Organization (BIO) will begin accepting nominations for the Award today, February 22, 2017. 
Read More

BIO Submits Comments on EPA Renewables Enhancement and Growth Support Rule
Press Release  •  February 16, 2017
The Biotechnology Innovation Organization (BIO) today submitted comments on the Environmental Protection Agency’s recently proposed Renewables Enhancement and Growth Support (REGS) Rule. BIO supports EPA’s ongoing efforts to improve the efficiency and effectiveness of the federal Renewable Fuel Standards (RFS).
Read More

BIO Comments on EPA’s Renewables Enhancement and Growth Support (REGS) Proposed Rule
Letters, Testimony & Comments  •  February 16, 2017
BIO supports EPA’s ongoing efforts to improve the efficiency and effectiveness of the federal Renewable Fuel Standard (“RFS”) program, which was created by Congress, with bipartisan support, in statutory provisions that President George W. Bush signed into law as part of the Energy Policy Act of 2005 and Energy Independence and Security Act of 2007.
Read More

BIO Statement on National Academies’ Consensus Study on Human Gene Editing
Press Release  •  February 14, 2017
Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement  regarding the Consensus Study on Human Gene Editing, released today by the Human Gene Editing Initiative of the National Academies of Sciences and Medicine (NAS/NAM)
Read More